ReviewHuman vaccines & immunotherapeutics2021
Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.
Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2021Pooled it
- Assessing the Impact of Rotavirus Vaccination in Iranian Children Under Five: An Agent-Based Modelling Approach.Health science reports · 2026Article
- Diverse processes in rotavirus vaccine development.Human vaccines & immunotherapeutics · 2025Review
- Trends and Geographic Distribution of Rotavirus Genotypes Among Children Aged Under 5 Years Hospitalized with Acute Gastroenteritis in India, 2019-2023.Indian journal of pediatrics · 2025Article
- Efficacy of rotavirus vaccines in Indonesia: A review of genotype distribution and impact.Narra J · 2025Review
- Article
- The prevalence of rotavirus infection among Congolese children younger than 5 years hospitalized for gastroenteritis 10 years after introduction of rotavirus vaccination.IJID regions · 2025Article
- Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.Pharmaceutics · 2024Review
- Genetic diversity of G9, G3, G8 and G1 rotavirus group A strains circulating among children with acute gastroenteritis in Vietnam from 2016 to 2021.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2024Article
- Article
- Article
- Article
- Article
- Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2.The Journal of general virology · 2023Article
- Potential impact of rotavirus vaccination on reduction of childhood diarrheal disease in India: An analysis of National Family Health Survey-5.Vaccine: X · 2023Article
- Increase in rotavirus prevalence with the emergence of genotype G9P[8] in replacement of genotype G12P[6] in Sabah, Malaysia.Archives of virology · 2023Article
- Clinical profile of children under 5 years of age with rotavirus diarrhoea in a hospital setting in Kisangani, DRC, after the introduction of the rotavirus vaccine, a cross-sectional study.BMC pediatrics · 2023Article
- Predicting indirect effects of rotavirus vaccination programs on rotavirus mortality among children in 112 countries.NPJ vaccines · 2023Article
- Human health implications of emerging diseases and the current situation in India's vaccine industry.Science in One Health · 2023Review
- Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.Human vaccines & immunotherapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus is the leading cause of severe dehydrating gastroenteritis and death due to diarrhea among children under 5, causing over 180,000 under-5 deaths annually. Safe, effective rotavirus vaccines have been available for over a decade and are used in over 98 countries. In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure - ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. In this review, we summarize the available clinical trial and post-introduction evidence for these three new orally administered rotavirus vaccines. All three vaccines have demonstrated safety and efficacy against rotavirus diarrhea, although publicly available preclinical data are limited in some cases. This expanding product landscape presents a range of options to optimize immunization programs, and new presentations of each vaccine are currently under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.